From presentation to paper: gender disparities in oncological research

Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podia is unknown. We aim to identify gender-based differences in contributions to presentations at two major oncological conferences. Abstracts presented at plenary sessions of the American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical Oncology (ESMO) Congresses were collected. Trend analyses were used to analyze female contribution over time. The association between presenter's sex, study outcome (positive/negative) and journals' impact factors (IFs) of subsequently published papers was assessed using Chi-square and Mann-Whitney U tests. Of 166 consecutive abstracts presented at ASCO in 2011-2018 (n = 34) and ESMO in 2008-2018 (n = 132), 21% had female presenters, all originating from Northern America (n = 17) or Europe (n = 18). The distribution of presenter's sex was similar over time (p = 0.70). Of 2,425 contributing authors to these presented abstracts, 28% were women. The proportion of female abstract authors increased over time (p <0.05) and was higher in abstracts with female (34%) compared to male presenters (26%; p <0.01). Presenter's sex was not associated with study outcome (p = 0.82). Median journals' IFs were lower in papers with a female first author (p <0.05). In conclusion, there is a clear gender disparity in research presentations at two major oncological conferences, with 28% of authors and 21% of presenters of these studies being female. Lack of visibility of female presenters could impair acknowledgement for their research, opportunities in their academic career and even hamper heterogeneity in research

Del Homo Videns al Homo Twitter : democracia y redes sociales

El Homo Twitter puede motivar revoluciones, tumbar dictadores, adelantar elecciones, cambiar preferencias electorales... como de hecho ha ocurrido en múltiples ocasiones. Pero su condición es vivir y morir en Twitter. La eventual repercusión de lo virtual en la realidad de una colectividad ya no le pertenece al Homo Twitter. Así, por ejemplo, en el momento que la indignación compartida y expresada en Twitter contra una injusticia se cristaliza en un movimiento social, que toma las calles y las plazas, justo en ese momento, desaparece el Homo Twitter para cederle su lugar al sujeto social o al activista político. En otras palabras, aunque se toquen en algún momento, lo virtual se queda en lo virtual y lo real en lo real.Índice PRESENTACIÓN César Cansino, Jorge Calles Santillana y Martín Echeverría 7 INTRODUCCIÓN 11 Viejas y nuevas tesis sobre el Homo Twitter César Cansino PRIMERA PARTE: LA DEMOCRACIA EN LA ERA DE LAS REDES SOCIALES 1.La democracia en la era de la desconfianza 29 Pierre Rosanvallon 2.El déficit democrático 43 Gianfranco Pasquino 3.Viejas y nuevas promesas de la democracia 57 César Cansino 4.La democracia y el desafío tecnológico 73 Ian Morris 5.Democracia, opinión pública y redes sociales 83 Javier Sánchez Galicia, Elías Aguilar García y César Cansino SEGUNDA PARTE: LAS REDES SOCIALES EN LA ERA DE LA DEMOCRACIA 6.Democracia 2.0: la política se introduce en las redes sociales 115 David Caldevilla Domínguez 7.Los rebeldes del presente: la acción en la era de la Web 2.0 137 Benjamín Arditi 8.Democracia digital y ciudadanía. El discurso político en Twitter 199 Juan Calvillo y Carlos Enrique Ahuactzin Martínez 9. Twitter: estructura y prácticas sociales 199 Jorge Calles Santillana 10. La rebelión del coro (o de cómo Twitter es intrínsecamente subversivo) 231 César Cansino TERCERA PARTE: DEMOCRACIA Y REDES SOCIALES EN UN PAÍS CAUTIVO 11. Twitter y sus perversiones: violencia y censura 251 Rossana Reguillo y Jesús Robles Maloof 12.¿Quién programa las redes sociales en Internet? El caso #YoSoy132 259 Luis César Torres Nabel 13.Entre mitos: Internet, redes sociales y participación política juvenil Martín Echeverría, José Antonio Meyer y César Cansino 287 14.Jóvenes y redes sociales 309 Octavio Islas Carmona 15. Twitter en números: motivaciones, hábitos y perfiles 333 Elías Aguilar García EPÍLOGO Homo Twitter, ¿fase superior del Homo Digital? 353 César Cansin

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations

Small‐cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next‐generation sequencing (NGS) and by characterizing a representative patient‐derived model. We performed targeted NGS, as well as comprehensive pathological evaluation, in 11 never/former light smokers with clinically diagnosed SCLC. We established a patient‐derived model from one such patient (DFCI168) harboring an NRASQ61K mutation and characterized the sensitivity of this model to MEK and TORC1/2 inhibitors. Despite the clinical diagnosis of SCLC, the majority (8/11) of cases were either of nonpulmonary origin or of mixed histology and included atypical carcinoid (n = 1), mixed non‐small‐cell lung carcinoma and SCLC (n = 4), unspecified poorly differentiated carcinoma (n = 1), or small‐cell carcinoma from different origins (n = 2). RB1 and TP53 mutations were found in four and five cases, respectively. Predicted driver mutations were detected in EGFR (n = 2), NRAS (n = 1), KRAS (n = 1), BRCA1 (n = 1), and ATM (n = 1), and one case harbored a TMPRSS2‐ERG fusion. DFCI168 (NRASQ61K) exhibited marked sensitivity to MEK inhibitors in vitro and in vivo. The combination of MEK and mTORC1/2 inhibitors synergized to prevent compensatory mTOR activation, resulting in prolonged growth inhibition in this model and in three other NRAS mutant lung cancer cell lines. SCLC in never/former light smokers is rare and is potentially a distinct disease entity comprised of oncogenic driver mutation‐harboring carcinomas morphologically and/or clinically mimicking SCLC. Comprehensive pathologic review integrated with genomic profiling is critical in refining the diagnosis and in identifying potential therapeutic options

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

Purpose: This study examined safety, pharmacokinetics, and efficacy of veliparib, a PARP inhibitor, combined with carboplatin and etoposide in patients with extensive-stage (ED) small cell lung cancer (SCLC) and other solid tumors. Patients and Methods: The 3 thorn 3 design was used for dose escalation of oral veliparib in combination with carboplatin (AUC 5 on day 1) and etoposide (100 mg/m(2) on days 1-3) in 21-day cycles. Veliparib dose was explored from 80 to 240 mg b.i.d. on 7-day, 14-day, or continuous schedules. Patients without disease progression continued on maintenance monotherapy (veliparib 400 mg b.i.d.) until disease progression or unacceptable toxicity. Results: Thirty-nine patients were enrolled to determine the recommended phase II dose of 240 mg veliparib for 14 days combined with carboplatin and etoposide based on long-term tolerability. Dose-limiting toxicity occurred in 1 patient (grade 2 toxic motor polyneuropathy) at veliparib 240 mg b.i.d. for 7 days. Most common adverse events related to veliparib were nausea (39%), fatigue (39%), and hematologic toxicities. Continuous dosing of veliparib 240 mg b.i.d. with carboplatin and etoposide resulted in excessive chemotherapy dose delays due to hematologic toxicity (grade 3/4 neutropenia/thrombocytopenia). Etoposide pharmacokinetics was not affected by veliparib. Confirmed responses occurred in 17 of 39 (44%) and 16 of 25 (64%) of all enrolled and ED SCLC patients, respectively. At the RP2D, confirmed responses occurred in 6 of 13 (46%) and 5 of 6 (83%) of all enrolled and ED SCLC patients, respectively. Conclusions: Veliparib (240 mg b.i.d. 14 days) plus carboplatin/etoposide can be safely combined. Phase II of this study is ongoing in first-line patients with ED SCLC

Del Homo Videns al Homo Twitter : democracia y redes sociales

El Homo Twitter puede motivar revoluciones, tumbar dictadores, adelantar elecciones, cambiar preferencias electorales... como de hecho ha ocurrido en múltiples ocasiones. Pero su condición es vivir y morir en Twitter. La eventual repercusión de lo virtual en la realidad de una colectividad ya no le pertenece al Homo Twitter. Así, por ejemplo, en el momento que la indignación compartida y expresada en Twitter contra una injusticia se cristaliza en un movimiento social, que toma las calles y las plazas, justo en ese momento, desaparece el Homo Twitter para cederle su lugar al sujeto social o al activista político. En otras palabras, aunque se toquen en algún momento, lo virtual se queda en lo virtual y lo real en lo real.Índice PRESENTACIÓN César Cansino, Jorge Calles Santillana y Martín Echeverría 7 INTRODUCCIÓN 11 Viejas y nuevas tesis sobre el Homo Twitter César Cansino PRIMERA PARTE: LA DEMOCRACIA EN LA ERA DE LAS REDES SOCIALES 1.La democracia en la era de la desconfianza 29 Pierre Rosanvallon 2.El déficit democrático 43 Gianfranco Pasquino 3.Viejas y nuevas promesas de la democracia 57 César Cansino 4.La democracia y el desafío tecnológico 73 Ian Morris 5.Democracia, opinión pública y redes sociales 83 Javier Sánchez Galicia, Elías Aguilar García y César Cansino SEGUNDA PARTE: LAS REDES SOCIALES EN LA ERA DE LA DEMOCRACIA 6.Democracia 2.0: la política se introduce en las redes sociales 115 David Caldevilla Domínguez 7.Los rebeldes del presente: la acción en la era de la Web 2.0 137 Benjamín Arditi 8.Democracia digital y ciudadanía. El discurso político en Twitter 199 Juan Calvillo y Carlos Enrique Ahuactzin Martínez 9. Twitter: estructura y prácticas sociales 199 Jorge Calles Santillana 10. La rebelión del coro (o de cómo Twitter es intrínsecamente subversivo) 231 César Cansino TERCERA PARTE: DEMOCRACIA Y REDES SOCIALES EN UN PAÍS CAUTIVO 11. Twitter y sus perversiones: violencia y censura 251 Rossana Reguillo y Jesús Robles Maloof 12.¿Quién programa las redes sociales en Internet? El caso #YoSoy132 259 Luis César Torres Nabel 13.Entre mitos: Internet, redes sociales y participación política juvenil Martín Echeverría, José Antonio Meyer y César Cansino 287 14.Jóvenes y redes sociales 309 Octavio Islas Carmona 15. Twitter en números: motivaciones, hábitos y perfiles 333 Elías Aguilar García EPÍLOGO Homo Twitter, ¿fase superior del Homo Digital? 353 César Cansin

From presentation to paper: Gender disparities in oncological research

Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podia is unknown. We aim to identify gender-based differences in contributions to presentations at two major oncological conferences. Abstracts presented at plenary sessions of the American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical Oncology (ESMO) Congresses were collected. Trend analyses were used to analyze female contribution over time. The association between presenter's sex, study outcome (positive/negative) and journals' impact factors (IFs) of subsequently published papers was assessed using Chi-square and Mann–Whitney U tests. Of 166 consecutive abstracts presented at ASCO in 2011–2018 (n = 34) and ESMO in 2008–2018 (n = 132), 21% had female presenters, all originating from Northern America (n = 17) or Europe (n = 18). The distribution of presenter's sex was similar over time (p = 0.70). Of 2,425 contributing authors to these presented abstracts, 28% were women. The proportion of female abstract authors increased over time (p < 0.05) and was higher in abstracts with female (34%) compared to male presenters (26%; p < 0.01). Presenter's sex was not associated with study outcome (p = 0.82). Median journals' IFs were lower in papers with a female first author (p < 0.05). In conclusion, there is a clear gender disparity in research presentations at two major oncological conferences, with 28% of authors and 21% of presenters of these studies being female. Lack of visibility of female presenters could impair acknowledgement for their research, opportunities in their academic career and even hamper heterogeneity in research

Estudio del mecanismo responsable de la superconductividad en los óxidos de cobre superconductores de itrio y lantano

IP 1101-05-402-93ARTICULO(S) EN REVISTA: Calculo de correlaciones entre TCy laspropiedades electronicas y fononicas en los;nuevos superconductores / Jairo Giraldo, R. Baquero - En:Revista Colombiana de Fisica No. 27 (1995); p.;595-598 - Thermoelectric power of (Bi-Pb)SrCaCuO superconductingthin films / J.E Rodriguez, A. Mariño, Jairo;Giraldo, H. Rodriguez - En: Revista Colombiana de Fisica Vol.28, no.2 (1996); p. 197-200 - Electron-phonon;enhancement of thermopower in si doped superconducting bicompounds / Jairo Giraldo, J. E Rodriguez, A. Mariño;- En: Revista Colombiana de Fisica No. 28 (1996); p. 189-1-92Optical andstructural properties of Cd1-iZniTe;for high Zn concentrations / J.J Perez Bueno, M. E Rodriguez,L.Baños, O.Zelaya-Angel, Jairo Giraldo - En:;Revista Colombiana de Fisica vol. 29 No. 2 (1997); p. 207-210-Incrementoen la interaccion e-ph en;compuestos superconductores de BSCCO dopados con Si y Ag /J.ERodriguez,A . Mariño, J. Giraldo - En: Revista;Colombiana de Fisica vol. 29 No. 2 (1997); p. 231-234 - Estudioelectronico del C60 con un modelo de ruptura;de la simetria esferica a la icosaedrica / F. Alonso, J. JGiraldo - En: Revista Colombiana de Fisica vol. 30;No 1 (1998); p. 173-176 - Some tracks to a conventional approachin the cuprates / Jairo Giraldo - En: Revista;Colombiana de Fisica vol. 30 No 1 (1998); p.177-180 - Breve historia de lasuperconductividad de alta;temperatura critica / Jairo Giraldo Gallo - En: Momento Revistadel departamento de Fisica Universidad;Nacional de Colombia No. 9 (abril : 1995); p. 52-63 - Algunosproblemas conceptuales y metodologicos en la;superconductividad de alta temperatura critica / Jairo GiraldoGallo - En:Momentos Revista del departamento;de Fisica Universidad Nacional de Colombia No 9 (abril : 1995);p. 64-78 -Calculated bonding, structural, and;vibrational properties of YBa2Cu3-xCoxO7 / U. Yxklinten, JairoGiraldo, K.Holmlund - En: Physica C. No 234;(1994); p. 295-299 - CAPITULO(S) EN LIBRO: Tight-binding calculation of the van hove singularity shift from;the fermi level as a function of x for La2-xBaxCuO4 / Jairo Giraldo, R. Baquero. - p. 135-142. -- En:;Manifestation of the E-Ph interaction - proceedings of the2 nd(CINVESTAV) superconductivity symposium -;Mexico : 1994. : il. ; 29 cm. - ISBN 9810215452 - ARTICULO(S)ENREVISTA:Lattice properties of YBa2Cu3-xCoxO7;: pilot calculation using effective medium theory / JairoGiraldo, U. Yxklinten - En: journal of;superconductivity vol. 8 No 1 (1995); p. 1-2 - Electron-phononcontribution to thermopower in si-doped;superconducting bi compounds / Jairo Giraldo, J. E Rodriguez,A.Mariño -En: Physical Review B. VOL. 56 No 5;(1997 : aug. 1); p. 2383-2386 - Transport and structural properties of YBa2Cu3O7-g thin films and bulk samples;as a function of oxygen content - En: Friday morning vol.43 No1 (1998);p. 964 - EMT Applied to complex;systems: lattice properties of YBa2Cu3-xCoxO7 / Jairo Giraldo,Uno Yxklinten - En: American institute of;Physics (1996); p. 461-465. - Termopower and lattice parametersof YBa2Cu3O7-g thin films as a function of;oxygen content / Jairo Giraldo, A. Pulzara, P. Prieto, M.Chacon'- en: Revista Mexicana de Fisica No 44 sup.;(1998 : dic); p. 202-207 - Electron-phonon enhancement ofthermopower in silver-doped superconducting bi;compounds / J. E. Rodriguez, A. Mariño, Jairo Giraldo - En: Physica C. 282-287 (1997); p. 1253-1254 - An;aproximation to the optical absorption spectra of the ternarycompound ZnSexTe1-x / J. C Salcedo, Jairo;Giraldo, A. Camacho - En: Revista Mexicana de Fisica No. 44 sup.(1998 : dic.); p. 119-121. - Electronic and;vibrational properties of the C60 molecule / F. Alonso Marroquin, Jairo Giraldo, A.Calles, J. J Castro - En:;Revista Mexicana de Fisica No 44 sup. (1998 : dic); p. 18-21

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

Intratumoral therapies, especially Toll-like receptor agonists, can trigger both the innate and adaptive immune systems. BO-112 is a nanoplexed form of polyinosinic:polycytidylic acid (poly I:C) that induces local and systemic immunotherapeutic effects in mouse models. In a multicenter phase 1 clinical trial, repeated intratumoral administrations of BO-112 induced an increase in tumor cell necrosis and apoptosis, as well as augmented immune reactivity according to gene expression profiling. The first three cohorts receiving BO-112 as a monotherapy resulted in a recommended dose of 1 mg that could be safely repeated. Two grade 3 to 4 adverse reactions in the form of reversible thrombocytopenia were reported. In a fourth cohort of 28 patients with tumors that had primary resistance to anti–programmed cell death protein–1 (PD-1), the combination of intratumoral BO-112 with nivolumab or pembrolizumab was also well tolerated, and 3 patients (2 with melanoma and 1 with renal cell carcinoma) achieved partial responses, with 10 more patients having stable disease at 8 to 12 weeks. Thus, local BO-112 combined with a systemic anti–PD-1 agent might be a strategy to revert anti–PD-1 resistanc